Can pregnant women take larotrectinib

Introduction: Larotrectinib has demonstrated significant efficacy in the treatment of tumors targeting specific genetic abnormalities. For the special group of pregnant women, extreme caution is required in its use. Since the drug may affect the normal development of the fetus through the placenta, pregnant women should fully understand the potential risks before using larotrectinib and make decisions under the guidance of a professional doctor. Considering that the residue of the drug in the body may be passed to the baby through milk, lactating women also need to avoid breastfeeding during the medication and within a specific period of time after stopping the medication to ensure the safety of the baby.

Precautions for use of larotrectinib in special populations

Use in pregnant women: The safety of larotrectinib in pregnant women has not been fully verified. In view of the unknown risks that the drug may have on the fetus, including but not limited to abnormal growth and development, organ damage, etc., pregnant women should avoid using larotrectinib unless there are no other safer alternative treatments and after strict evaluation by a doctor. In addition, if a pregnant woman has taken larotrectinib without knowing she is pregnant, she should consult a doctor immediately to understand the possible risks and follow-up treatment measures.

Dose for lactating women: Since may have adverse effects on nursing infants through milk secretion, lactating women are advised to suspend breastfeeding while taking larotrectinib and within 1 week after the last dose. During this period, other suitable feeding methods, such as formula milk, can be selected to ensure that the baby's nutritional needs are met.

Populations of reproductive potential: Women and men who plan to have children or have reproductive potential need to be fully evaluated before using larotrectinib. Women should take a pregnancy test before treatment to rule out the possibility of pregnancy. During treatment and for 1 week after the last dose, it is recommended to use effective contraceptive measures to prevent the risk of unwanted pregnancy. Likewise, men who have a female partner of reproductive potential should use contraceptive measures for a corresponding period of time.

Pediatric patients: As another special group, pediatric patients have different physiological functions from adults, so the use of larotrectinib must be under the guidance of a doctor. Doctors will develop a personalized treatment plan based on the child's age, weight, condition and other factors to ensure the safety and effectiveness of the drug.

Usage in elderly patients: For elderly patients, although the efficacy of larotrectinib is not significantly different from that of younger patients, considering other underlying diseases and drug metabolism characteristics that the elderly may have, it still needs to be used under the guidance of a doctor. The doctor will take the patient's overall health into consideration and formulate an appropriate medication plan.

Dose for patients with hepatic impairment: Patients with mild hepatic impairment generally do not need to adjust the dose when using larotrectinib, but changes in liver function should be closely monitored. For patients with moderate liver damage, it is recommended to use it with caution under the guidance of a doctor, and adjust the medication regimen according to the patient's specific condition.

Dosage in patients with renal impairment: For patients with renal impairment of any severity, the dose of larotrectinib generally does not require special adjustment. Doctors will still pay close attention to changes in the patient's kidney function, and patients must follow the doctor's instructions, take medications on time, and undergo relevant examinations regularly.